Compare SEDG & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SEDG | SNDX |
|---|---|---|
| Founded | 2006 | 2005 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.8B |
| IPO Year | 2015 | 2014 |
| Metric | SEDG | SNDX |
|---|---|---|
| Price | $33.59 | $22.12 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 19 | 13 |
| Target Price | $28.20 | ★ $80.69 |
| AVG Volume (30 Days) | ★ 3.3M | 1.1M |
| Earning Date | 01-01-0001 | 05-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 78.26 | 11.56 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,184,444,000.00 | $172,352,000.00 |
| Revenue This Year | $16.93 | $113.52 |
| Revenue Next Year | $12.92 | $52.49 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 31.39 | ★ 627.84 |
| 52 Week Low | $11.00 | $8.59 |
| 52 Week High | $48.60 | $22.73 |
| Indicator | SEDG | SNDX |
|---|---|---|
| Relative Strength Index (RSI) | 44.31 | 59.12 |
| Support Level | $30.04 | $19.46 |
| Resistance Level | $33.97 | $22.33 |
| Average True Range (ATR) | 3.54 | 1.01 |
| MACD | -0.61 | 0.14 |
| Stochastic Oscillator | 9.74 | 81.84 |
SolarEdge Technologies designs, develops, and sells direct current optimized inverter systems for solar photovoltaic installations. The company system consists of power optimizers, inverters, and cloud-based monitoring platform and addresses a broad range of solar market segments, from residential solar installations to commercial and small utility-scale solar installations. The company sells its products directly to solar installers, engineering, procurement, and construction firms and indirectly to solar installers through distributors and electrical equipment wholesalers.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.